NCT03289273 is a clinical trial of Regorafenib (Stivarga, BAY73-4506) in Liver Neoplasms, sponsored by Bayer.

Who is sponsoring NCT03289273?

NCT03289273 is sponsored by Bayer.

What drugs are being tested in NCT03289273?

Interventions in NCT03289273: Regorafenib (Stivarga, BAY73-4506).

What condition does NCT03289273 study?

NCT03289273 studies Liver Neoplasms.

Is NCT03289273 still recruiting?

NCT03289273 is currently completed. Last updated 13 June 2023.

Last reviewed 2023-06-13 · How we verify

NCT03289273

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

Completed Last updated 13 June 2023

What this trial tests

trial testing Regorafenib (Stivarga, BAY73-4506) in Liver Neoplasms in 1,010 participants. Completed in 21 June 2022.

Timeline

13 September 2017

Primary endpoint
31 January 2022

21 June 2022

Quick facts

Lead sponsor	Bayer
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,010
Start date	13 September 2017
Primary completion	31 January 2022
Estimated completion	21 June 2022
Sites	37 locations across Italy, Japan, Taiwan, South Korea, Denmark, Netherlands, Russia, Turkey (Türkiye)

Drugs / interventions tested

Regorafenib (Stivarga, BAY73-4506) — full drug profile →

Conditions studied

Liver Neoplasms — all drugs for Liver Neoplasms →

Sponsor

Bayer — full company profile →

Who can join

Eligibility, any sex, with Liver Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Experience with regorafenib in the treatment of hepatocellular carcinoma.
Granito A, Forgione A, Marinelli S, Renzulli M, et al · · 2021 · cited 97× · PMID 34104211 · DOI 10.1177/17562848211016959
Systemic Treatment Options in Hepatocellular Carcinoma.
Rimassa L, Pressiani T, Merle P. · · 2019 · cited 96× · PMID 31799201 · DOI 10.1159/000499765
Systemic Treatment for Advanced Hepatocellular Carcinoma.
Bouattour M, Mehta N, He AR, Cohen EI, et al · · 2019 · cited 84× · PMID 31768344 · DOI 10.1159/000496439
Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC.
Granito A, Marinelli S, Forgione A, Renzulli M, et al · · 2021 · cited 25× · PMID 34079777 · DOI 10.2147/jhc.s251729
Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine.
Duan J, Wu Y, Liu J, Zhang J, et al · · 2019 · cited 23× · PMID 31696097 · DOI 10.2147/jhc.s224849
Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting.
Falette-Puisieux M, Nault JC, Bouattour M, Lequoy M, et al · · 2023 · cited 15× · PMID 37547443 · DOI 10.1177/17588359231189425
Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study.
Kim YJ, Merle P, Finn RS, Kudo M, et al · · 2025 · cited 4× · PMID 40831889 · DOI 10.1159/000542285
Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States.
Finn RS, Iyer R, Kalman RS, Parikh ND, et al · · 2025 · cited 2× · PMID 39935697 · DOI 10.2147/jhc.s459983

Verify or expand the search:

Other trials of Regorafenib (Stivarga, BAY73-4506)

Trials testing the same drug.

NCT06137170 — A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Col · completed
NCT06321055 — An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal T · completed
NCT06246643 — A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer S · Phase 2 · active not recruiting
NCT06029010 — An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metast · completed
NCT04696055 — Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With · Phase 2 · completed

Other recruiting trials for Liver Neoplasms

Currently open trials in the same condition.

NCT07377487 — TheraSphere Japan Pre-Market Study · NA · recruiting
NCT07473687 — Feasibility Study of Non-Contact Imaging-Based Physiological Monitoring in the Operating Room · recruiting
NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
NCT07378709 — Exploratory Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma · recruiting
NCT06261814 — Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors · Phase 2 · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03289273 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 13 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03289273.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing